Abstract: The present invention relates to a composition which is for preventing or treating bone diseases and includes CCR2 as an active ingredient. It was confirmed that a C—C chemokine receptor type 2 (CCR2) protein, a polynucleotide encoding the CCR2 protein, or a mesenchymal stem cell transduced with the CCR2 according to the present invention neutralize bone disease factor MCP-1, thereby reducing the collagen epitope (CTX-II) and collagen metabolism factors (MMP1 and MMP3) relating to collagen absorption in the body. In addition, it was confirmed that the expression of the SOX9 gene and anti-inflammatory cytokines (TGF-? and IL-10) related to cartilage differentiation was significantly increased. Thus, the present invention has excellent regenerative ability against osteoarthritis and excellent pain suppression and alleviation effects, and thus can be effectively used for preventing or treating bone diseases such as osteoarthritis.

Abstract: Disclosed are a composition for inducing immunity against an active ingredient and a method for preparing same, the composition comprising: a nucleic acid, a polypeptide, or a combination thereof as the active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the active ingredient is encapsulated in a nanoparticle structure formed by the amphiphilic block copolymer and the polylactate.

Abstract: The present invention relates to: a virus-containing pharmaceutical composition, which comprises, as an active ingredient, a virus for treating or preventing disease; and a preparation method therefor.

Abstract: The present invention relates to a technique for the T7 promoter-driven expression of a foreign protein, preferably, a human protein in E. coli having no T7 RNA polymerase. More particularly, the present invention relates to use of a vector including a T7 promoter and an N-terminal HA tag sequence for overexpression of a foreign protein in E. coli having no T7 RNA polymerase, E. coli that includes the vector and is able to overexpress the foreign protein in the absence of T7 RNA polymerase, a method for expressing or producing the foreign protein using the E. coli, and a method for analyzing functions of the foreign protein. Further, the present invention relates to a simple, rapid method for evaluating the expression and cytotoxicity of a human protein in E. coli by using the vector.

Abstract: The present invention relates to a technique for the T7 promoter-driven expression of a foreign protein, preferably, a human protein in E. coli having no T7 RNA polymerase. More particularly, the present invention relates to use of a vector including a T7 promoter and an N-terminal HA tag sequence for overexpression of a foreign protein in E. coli having no T7 RNA polymerase, E. coli that includes the vector and is able to overexpress the foreign protein in the absence of T7 RNA polymerase, a method for expressing or producing the foreign protein using the E. coli, and a method for analyzing functions of the foreign protein. Further, the present invention relates to a simple, rapid method for evaluating the expression and cytotoxicity of a human protein in E. coli by using the vector.